Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Retigabine.

Roger J Porter1, Virinder Nohria, Chris Rundfeldt

  • 1Department of Pediatrics, School of Medicine, Emory University, Atlanta, Georgia 30322, USA. rjportermd@aol.com

Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|January 3, 2007
PubMed
Summary
This summary is machine-generated.

Retigabine, a novel potassium channel opener, shows promise as an antiseizure and pain medication. Extensive phase I and II studies indicate a maximal tolerated dose of 1,200 mg/day with mild CNS side effects, and it is now in phase III trials.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Seletracetam Revisited: A Missed Opportunity for Effective Epilepsy Therapy.

CNS drugs·2026
Same author

Seletracetam Revisited: A Missed Opportunity for Effective Epilepsy Therapy.

CNS drugs·2026
Same author

Intranasal Seletracetam in a Patient with Reading Epilepsy: First-in-Human Use to Prevent Reflex Seizures.

Annals of neurology·2025
Same author

Brivaracetam effectiveness and patient-reported outcomes in clinical practice: Data from a 12-month prospective, observational study in the United States.

Epilepsy & behavior : E&B·2025
Same author

Interim analysis of the long-term efficacy and safety of azetukalner in an ongoing open-label extension study following a phase 2b clinical trial (X-TOLE) in adults with focal epilepsy.

Epilepsia open·2025
Same author

A comparison of the antiepileptogenic efficacy of two rationally chosen multitargeted drug combinations in a rat model of posttraumatic epilepsy.

Experimental neurology·2024
Same journal

FGF17 synergistically targets neuronal survival and oligodendrogenesis to restore stroke deficits.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Sotagliflozin improves cognitive deficits and attenuates neuroinflammation of Alzheimer's disease.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Neurological complications of current and emerging CAR-T cell therapies.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Hemodynamics Beyond Ischemic Zone Underlies Early Neurological Deterioration in Minor Stroke with Large Vessel Occlusion.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Nervonic acid and the long arc of therapeutic hope in X-linked adrenoleukodystrophy.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Long-term efficacy of subthalamic nucleus deep brain stimulation in focal motor seizures and implications for candidate selection.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
See all related articles

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Retigabine is a novel potassium channel opener.
  • It exhibits activity in animal models of epilepsy and preclinical pain models.

Purpose of the Study:

  • To evaluate the efficacy and safety of retigabine.
  • To determine the maximal tolerated dose and adverse effects.

Main Methods:

  • Phase I and II clinical studies.
  • Preclinical animal models for epilepsy and pain.

Main Results:

  • Retigabine demonstrated broad activity in epilepsy and pain models.
  • Maximal tolerated dose established at 1,200 mg/day.
  • Adverse effects were primarily mild and CNS-related, occurring during dose titration.

Conclusions:

  • Retigabine is a promising novel drug for epilepsy and pain.
  • Further investigation in pivotal phase III studies is ongoing.